Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02496767 · ClinicalTrials.gov registry record · Phase 3
Ventilatory Investigation of Tirasemtiv and Assessment of Longitudinal Indices After Treatment for a Year
A Phase 3 study, sponsored by Cytokinetics.
- Completed
- Registry status
- Phase 3
- Development phase
- 744
- Enrollment target
NCT02496767: Completed Phase 3 study, sponsored by Cytokinetics.
NCT02496767 is a Phase 3 study that has completed, run by Cytokinetics. The registered enrollment target is 744 participants, roughly in line with the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02496767, a Phase 3 study, has completed, sponsored by Cytokinetics.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 744 participants
- Enrollment target
Study Summary
This study assessed the effect of tirasemtiv versus placebo on respiratory function in patients with ALS.
Primary Outcome
SVC was measured using a spirometer (in units of liters). Following 3 to 5 breaths at rest, the patients were instructed to take as deep an inspiration as possible followed by a maximum exhalation (blowing out all the air in their lungs). Values obtained were converted to % predicted values (ie, the test result as a percent of predicted values for patients of similar demographic and baseline characteristics \[eg, height, age, sex\], based on Knudson 83 normative values).
Interventions
- DRUG Placebo tablets
- DRUG Tirasemtiv
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 744 participants |
| Start Date | 2015-09-03 |
| Est. Completion | 2017-09-27 |
| Phase | Phase 3 |
What the finished NCT02496767 record still lists
NCT02496767 is an interventional study that assigns participants to a tested intervention. The registered 744 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target.
The record links to 0 conditions, and to 2 interventions - of which Placebo tablets is the first listed.
NCT02496767 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02496767 about?
NCT02496767 is a clinical study titled "Ventilatory Investigation of Tirasemtiv and Assessment of Longitudinal Indices After Treatment for a Year". This study assessed the effect of tirasemtiv versus placebo on respiratory function in patients with ALS.
What is the current status of trial NCT02496767?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 744 participants. The study started on 2015-09-03. Estimated completion is 2017-09-27.
What interventions are being tested in trial NCT02496767?
The interventions under investigation include: Placebo tablets (DRUG), Tirasemtiv (DRUG).
Who is sponsoring clinical trial NCT02496767?
This trial is sponsored by Cytokinetics, which has 31 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02496767's enrollment target sits among peer trials
744 475th of 2000 higher than 1,525 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05619185 · 744 participants · NA
A SMART Evaluation of an Adaptive Web-based AUD Treatment for Service Members and Their Partners
- NCT06417814 · 744 participants · Phase 3
A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer
- NCT07046351 · 744 participants · NA
weSIPsmarter: Evaluating a Digital Health Intervention Aimed at Reducing Sugary Drinks Among Rural Head Start Preschoolers and Their Parents
- NCT07199569 · 744 participants · Phase 2
Comparability Trial of the MVA-BN Vaccine Manufactured in Different Production Cells
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI